Irina Isakova-Sivak, Larisa Rudenko: A promising inactivated whole-virion SARS-CoV-2 vaccine. Lancet Inf Dis, 15. Oktober 2020, doi:10.1016/S1473-3099(20)30832-X
Xiaoming Yang: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults - A Randomized Clinical Trial. JAMA, 26. Mai 2021, doi:10.1001/jama.2021.8565.
Xiaoming Yang et al.: Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2, Cell, 6. August 2020, doi:10.1016/j.cell.2020.06.008
Xiaoming Yang et al.: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Inf DIs, 15. Oktober 2020, doi:10.1016/S1473-3099(20)30831-8.
Guo-Lin Wang: Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization. NEJM, 6. April 2021, doi:10.1056/NEJMc2103022
Kirsten Vannice, Melanie Marti: Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine. SAGE Working Group on COVID-19-vaccines, 29. April 2021, online verfügbar als pdf; zuletzt abgerufen am 4. Juni 2021
who.int
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations, Pressemitteilung der WHO vom 7. Mai 2021, online abrufbar als html; zuletzt abgerufen am 4. Juni 2021